Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aldeyra Therapeu (ALDX)

Aldeyra Therapeu (ALDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 106,524
  • Shares Outstanding, K 60,183
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,850 K
  • EBIT $ -35 M
  • EBITDA $ -36 M
  • 60-Month Beta 0.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.50

Options Overview Details

View History
  • Implied Volatility 212.17% (-37.35%)
  • Historical Volatility 375.81%
  • IV Percentile 73%
  • IV Rank 40.25%
  • IV High 442.70% on 01/20/26
  • IV Low 56.89% on 08/08/25
  • Expected Move (DTE 3) 0.0425 (2.45%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 405
  • Volume Avg (30-Day) 6,759
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 18,406
  • Open Int (30-Day) 40,280
  • Expected Range 1.6925 to 1.7775

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +62.15%
on 03/17/26
5.7400 -69.77%
on 03/02/26
-3.7250 (-68.22%)
since 02/27/26
3-Month
1.0700 +62.15%
on 03/17/26
5.9300 -70.74%
on 01/30/26
-3.5750 (-67.33%)
since 12/26/25
52-Week
1.0700 +62.15%
on 03/17/26
6.5500 -73.51%
on 03/31/25
-4.9350 (-73.99%)
since 03/28/25

Most Recent Stories

More News
Did Aldeyra Therapeutics, Inc. (ALDX) Mislead Investors? Levi & Korsinsky Investigates

New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ:...

ALDX : 1.6800 (-5.08%)
Fraud Investigation: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Shareholders

New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ:...

ALDX : 1.6800 (-5.08%)
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX

NEW YORK , March 26, 2026 /PRNewswire/ -- 

ALDX : 1.6800 (-5.08%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX).  Such investors...

ALDX : 1.6800 (-5.08%)
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Drug Approval Prospects: Levi & Korsinsky

Aldeyra Therapeutics Stock Falls After FDA Issues Complete Response Letter Rejecting Reproxalap for Dry Eye Disease

ALDX : 1.6800 (-5.08%)
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX

NEW YORK , March 21, 2026 /PRNewswire/ --

ALDX : 1.6800 (-5.08%)
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALDX

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)...

ALDX : 1.6800 (-5.08%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors...

ALDX : 1.6800 (-5.08%)
Potential Securities Fraud: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX)

New York, New York--(Newsfile Corp. - March 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ:...

ALDX : 1.6800 (-5.08%)
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt...

ALDX : 1.6800 (-5.08%)

Business Summary

Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 1.9067
2nd Resistance Point 1.8733
1st Resistance Point 1.8217
Last Price 1.6800
1st Support Level 1.7367
2nd Support Level 1.7033
3rd Support Level 1.6517

See More

52-Week High 6.5500
Fibonacci 61.8% 4.4566
Fibonacci 50% 3.8100
Fibonacci 38.2% 3.1634
Last Price 1.6800
52-Week Low 1.0700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.